Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1181. doi: 10.1158/1535-7163.MCT-19-0471. No abstract available.

2.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1180. doi: 10.1158/1535-7163.MCT-19-0470. No abstract available.

3.

Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1179. doi: 10.1158/1535-7163.MCT-19-0469. No abstract available.

4.

Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272].

Dasmahapatra G, Nguyen TK, Dent P, Grant S.

Leuk Res. 2019 Jul;82:46-47. doi: 10.1016/j.leukres.2019.03.002. Epub 2019 May 10. No abstract available.

PMID:
31079870
5.

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.

Yu C, Dasmahapatra G, Dent P, Grant S.

Leukemia. 2016 Jun;30(6):1452. doi: 10.1038/leu.2016.7. Epub 2016 Apr 8. No abstract available.

PMID:
27055874
6.

In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1181.

7.
8.

PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S.

Clin Cancer Res. 2013 Jan 15;19(2):404-14. doi: 10.1158/1078-0432.CCR-12-2799. Epub 2012 Nov 30.

9.

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2012 May;11(5):1122-32. doi: 10.1158/1535-7163.MCT-12-0021. Epub 2012 Mar 12. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1180.

10.

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S.

Mol Cancer Ther. 2011 Sep;10(9):1686-97. doi: 10.1158/1535-7163.MCT-10-1108. Epub 2011 Jul 12. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1179.

11.

Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.

Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M, Dasmahapatra G, Yacoub A, Dent P, Dmitriev IP, Curiel DT, Grant S, Pellecchia M, Reed JC, Sarkar D, Fisher PB.

Cancer Res. 2010 Jun 15;70(12):5034-45. doi: 10.1158/0008-5472.CAN-10-0563. Epub 2010 May 25.

12.

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S.

Blood. 2010 Jun 3;115(22):4478-87. doi: 10.1182/blood-2009-12-257261. Epub 2010 Mar 16. Retraction in: Blood. 2019 Jul 4;134(1):95.

13.

Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.

Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S.

Cancer Biol Ther. 2009 May;8(9):808-19. Epub 2009 May 8. Erratum in: Cancer Biol Ther. 2019;20(9):1300.

14.
15.
16.

Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

Dasmahapatra G, Almenara JA, Grant S.

Mol Pharmacol. 2006 Jan;69(1):288-98. Epub 2005 Oct 11. Retraction in: Mol Pharmacol. 2019 Apr;95(4):335.

PMID:
16219908
18.

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.

Yu C, Dasmahapatra G, Dent P, Grant S.

Leukemia. 2005 Sep;19(9):1579-89. Retraction in: Leukemia. 2016 Jun;30(6):1452.

PMID:
16015388
19.

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.

Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK.

Clin Cancer Res. 2004 Aug 1;10(15):5242-52.

20.

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK.

Mol Cancer Ther. 2003 Nov;2(11):1093-103.

Supplemental Content

Loading ...
Support Center